Showing 3671-3680 of 6035 results for "".
- EU Seals Deal For Up to 300 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/eu-seals-deal-for-up-to-300-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478528/The European Commission on Wednesday said it has finalized an advance purchase agreement with Pfizer and BioNTech for the initial supply of 200 million doses of their experimental COVID-19 vaccine, with an option to request up to a 100 million more. The announcement comes days after the companies
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- AAO Data: Experimental RNA Based Drug Addresses the Underlying Cause of Rare Eye Diseasehttps://modernod.com/news/aao-data-experimental-rna-based-drug-addresses-the-underlying-cause-of-rare-eye-disease/2478509/At the virtual AAO 2020 meeting, ProQR Therapeutics will present two posters on its lead product candidate sepofarsen for the treatment of the root cause of Leber congenital amaurosis 10 (LCA10), a rare eye disease that damages the development of the retina and causes severe vision loss. P
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for Lytenava for Retinal Diseaseshttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-of-open-label-safety-study-for-lytenava-for-retinal-diseases/2478490/Outlook Therapeutics announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/Lytenava (NORSE THREE). Patient enrollment for the study was completed in less than 1 month, ahead of the planned 4-month enrollment schedule.
- Lineage Cell Therapeutics to Host Expert Call Following OpRegen Data Update at 2020 AAO Meetinghttps://modernod.com/news/lineage-cell-therapeutics-to-host-expert-call-following-opregen-data-update-at-2020-aao-meeting/2478483/Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for
- Lilly Reaches Deal to Supply US With COVID-19 Antibody Treatment Bamlanivimabhttps://modernod.com/news/lilly-reaches-deal-to-supply-us-with-covid-19-antibody-treatment-bamlanivimab/2478472/Eli Lilly announced that it has signed a $375-million agreement with the US government to supply 300,000 vials of bamlanivimab, an investigational neutralizing antibody treatment for COVID-19. The company recently submitted a request to the FDA seeking emergency-use authorization (EUA) for bamlan
- Visus Therapeutics Expands Clinical Advisory Board With Appointment of Renowned Ophthalmologistshttps://modernod.com/news/visus-therapeutics-expands-clinical-advisory-board-with-appointment-of-renowned-ophthalmologists/2478453/Visus Therapeutics announced the appointments of prominent ophthalmologists Marguerite McDonald, MD, Neda Shamie, MD, William Trattler, MD, and Lawrence Woodard, MD, to its clinical advisory board. Drs. McDonald, Shamie, Trattler and Woodard will lend their decades of experience in clinical pract
- Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu
- Low Vision Resources and Rehabilitation for Retinal Degeneration Patients: A Webinar to Discuss Critical Needs and Opportunitieshttps://modernod.com/news/low-vision-resources-and-rehabilitation-for-retinal-degeneration-patients-a-webinar-to-discuss-critical-needs-and-opportunities/2478431/The Foundation Fighting Blindness is hosting a low vision webinar to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients. The interactive webinar is appropriate for all eye care professional